Arcadia Biosciences (Nasdaq: RKDA) is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| RKDA | Arcadia Biosciences, Inc. | 2025-12-01 15:59:09 | 3.7 | 0.11 | 3.05 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RKDA | 0001469443 | Arcadia Biosciences, Inc. | US0390143032 | 54930027ZPNA80B8O763 | 810571538 | Nasdaq | 1311 | Crude Petroleum & Natural Gas | 1231 | DE | 5956 SHERRY LANE | DALLAS | TX | 75225 | UNITED STATES | US | 214-974-8921 | 5956 SHERRY LANE, DALLAS, TX | 5956 SHERRY LANE, DALLAS, TX | — | agricultural biotechnology | 2002 | Matthew Plavan | 42 | https://arcadiabio.com/ | 4,184,025 | 1,367,429 | 1,373,120 | Arcadia Biosciences (Nasdaq: RKDA) is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation. | 2025-11-27 20:58:12 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 4,184,025 | 14,953 | 0.3587 | 1,367,040 | 4,200 | 0.3082 |
| 2023 | 4,169,072 | -16,858,528 | -80.1733 | 1,362,840 | 505,268 | 58.9184 |
| 2022 | 21,027,600 | -32,217,400 | -60.5078 | 857,572 | -21,331,346 | -96.1351 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Mark Kawakami | Chief Financial Officer | 2024 | 212,742 | 53,016 | 0 | 57,802 | 2,727 | 370,175 |
| Laura Pitlik | Chief Marketing Officer | 2024 | 88,942 | 0 | 0 | 0 | 65,885 | 154,826 |
| Stanley E. Jacot, Jr. | President, Chief Executive Officer | 2024 | 230,031 | 0 | 0 | 0 | 288,077 | 518,108 |
| Thomas J. Schaefer | President, Chief Executive Officer | 2024 | 260,000 | 65,000 | 0 | 126,853 | 3,736 | 499,477 |
| Stanley E. Jacot | Chief Executive Officer, President | 2023 | 350,000 | 0 | 0 | 165,156 | 0 | 525,177 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 9 |
| 2023 | 21 |
| 2022 | 30 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 5,045,000 | 5,330,000 | 9,956,000 |
| Cost Of Revenue | 2,963,000 | 3,300,000 | 9,802,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 53,000 | 1,387,000 | 1,509,000 |
| General And Administrative Expenses | 9,641,000 | 14,508,000 | 18,048,000 |
| Operating Expenses | 8,693,000 | 19,268,000 | 28,771,000 |
| Operating Income | -3,648,000 | -13,938,000 | -18,815,000 |
| Net Income | -7,038,000 | -13,981,000 | -15,376,000 |
| Earnings Per Share Basic | -5.17 | -11.3 | -25.65 |
| Earnings Per Share Diluted | -5.17 | -11.3 | -25.65 |
| Weighted Average Shares Outstanding Basic | 1,363,303 | 1,236,934 | 599,389 |
| Weighted Average Shares Outstanding Diluted | 1,363,303 | 1,236,934 | 599,389 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 4,242,000 | 6,518,000 | 20,644,000 |
| Marketable Securities Current | 0 | 5,124,000 | — |
| Accounts Receivable | 1,894,000 | 514,000 | 1,287,000 |
| Inventories | 904,000 | 1,958,000 | 2,571,000 |
| Non Trade Receivables | 1,894,000 | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 9,242,000 | 14,972,000 | 25,398,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 41,000 | 384,000 | 704,000 |
| Other Assets Non Current | 92,000 | 164,000 | 165,000 |
| Total Assets Non Current | 4,275,000 | 4,733,000 | 3,524,000 |
| Total Assets | 13,517,000 | 19,705,000 | 28,922,000 |
| Accounts Payable | 703,000 | 801,000 | 931,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 30,000 | 58,000 | 270,000 |
| Total Liabilities Current | 2,563,000 | 3,590,000 | 4,209,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 2,000,000 | 2,000,000 | 2,000,000 |
| Total Liabilities Non Current | 4,731,000 | 3,412,000 | 3,813,000 |
| Total Liabilities | 7,294,000 | 7,002,000 | 8,022,000 |
| Common Stock | 65,000 | 65,000 | 65,000 |
| Retained Earnings | -278,878,000 | -271,840,000 | -257,859,000 |
| Accumulated Other Comprehensive Income | 0 | 101,000 | — |
| Total Shareholders Equity | 6,223,000 | 12,841,000 | 21,033,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 58,000 | 287,000 | 439,000 |
| Share Based Compensation Expense | 512,000 | 717,000 | 1,106,000 |
| Other Non Cash Income Expense | 0 | 40,000 | 314,000 |
| Change In Accounts Receivable | 762,000 | -184,000 | -592,000 |
| Change In Inventories | -550,000 | 2,419,000 | -1,118,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -303,000 | -522,000 | -757,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -9,627,000 | -15,294,000 | -13,977,000 |
| Purchases Of Marketable Securities | 0 | 7,525,000 | — |
| Sales Of Marketable Securities | — | — | 0 |
| Acquisition Of Property Plant And Equipment | 16,000 | 5,000 | 72,000 |
| Acquisition Of Business | — | — | 0 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 7,342,000 | -4,344,000 | 1,417,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 9,000 | 12,000 | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 9,000 | 5,512,000 | 4,519,000 |
| Change In Cash | -2,276,000 | -14,126,000 | -8,041,000 |
| Cash At End Of Period | 4,242,000 | 6,518,000 | 20,644,000 |
| Income Taxes Paid | — | — | 0 |
| Interest Paid | 782,000 | 0 | 1,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -5.17 | -11.3 | -25.65 |
| Price To Earnings Ratio | -1.1451 | -0.277 | -0.4226 |
| Earnings Growth Rate | -54.2478 | -55.9454 | — |
| Price Earnings To Growth Ratio | 0.0211 | 0.005 | — |
| Book Value Per Share | 4.5646 | 10.2697 | 34.8688 |
| Price To Book Ratio | 1.2969 | 0.3048 | 0.3109 |
| Ebitda | -6,198,000 | -12,999,000 | -14,648,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -285,000 | -33,000 | -1,148,000 |
| Free Cash Flow | -9,342,000 | -15,261,000 | -12,829,000 |
| Return On Equity | -1.131 | -1.0888 | -0.731 |
| One Year Beta | 0.8111 | 0.016 | 1.0616 |
| Three Year Beta | 0.8311 | 0.9006 | 1.0389 |
| Five Year Beta | 0.9458 | 0.8365 | 0.9057 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Schaefer Thomas J. | Chief Executive Officer | 2025-05-09 | 12,500 | A | 37,975 |
| Kawakami Mark | Chief Financial Officer | 2025-05-09 | 12,500 | A | 33,987 |
| Schaefer Thomas J. | Chief Executive Officer | 2025-02-03 | 700 | A | 2,819 |
| Kawakami Mark | Chief Financial Officer | 2025-02-03 | 700 | A | 2,681 |
| Schaefer Thomas J. | Chief Executive Officer | 2024-08-19 | 20,000 | A | 25,475 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Mariner, LLC | 2025-09-30 | 42,556 | 12,264 | 3.47 |
| MORGAN STANLEY | 2025-09-30 | 2,110 | 608 | 3.4704 |
| BANK OF AMERICA CORP /DE/ | 2025-09-30 | 41 | 12 | 3.4167 |
| OSAIC HOLDINGS, INC. | 2025-09-30 | 260 | 75 | 3.4667 |
| DRW Securities, LLC | 2025-09-30 | 34,811 | 10,032 | 3.47 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD INDEX FUNDS | 2025-09-30 | Institutional Select Shares | VSEMX | 9,644 | 33,464.68 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-09-30 | Institutional Plus Shares | VEMPX | 9,644 | 33,464.68 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-09-30 | ETF Shares | VXF | 9,644 | 33,464.68 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-09-30 | Institutional Shares | VIEIX | 9,644 | 33,464.68 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-09-30 | Admiral Shares | VEXAX | 9,644 | 33,464.68 | 0.0 |